The COVID-19 pandemic had a negative impact on multiple industries and decreased the demand for many medical devices and pharmaceutical products. Even though the larger number of hospitalizations due to complications caused by the virus has created an increase in demand for certain products, the overall demand for intravenous (IV) solutions went down in the
Antonio ColletAfter COVID-19, Demand for Intravenous Solutions Shows Signs of Recovery
OncoSec and Inovio Pharmaceuticals have announced they are testing potential COVID-19 vaccines and pursuing first-in-human Phase 1 clinical trials. As of April 9, the FDA has not approved any preventative or therapeutic coronavirus vaccines for use against the SARS-CoV-2 coronavirus (COVID-19). While OncoSec has submitted an investigational new drug (IND) application for its vaccine, CORVax12,
iData ResearchOncoSec and Inovio Pursuing Phase 1 Clinical Trials for COVID-19 Vaccine
Coronavirus and Ibuprofen: Is it safe to take? Medical professionals no longer recommend using ibuprofen to manage coronavirus symptoms. The health minister of France, Olivier Véran has warned citizens to avoid taking ibuprofen to treat symptoms of the coronavirus after a report was published linking “grave adverse effects” to the use of anti-inflammatory drugs (NSAIDs).
iData ResearchCoronavirus and Ibuprofen: Is it safe to take?
Register to receive a free Global Immunology Drugs Market Report Suite report synopsis and brochure The Japan Ministry of Health, Labour and Welfare has recently approved AbbVie’s Skyrizi for treatment of three categories of psoriasis and psoriatic arthritis. This international approval is the first to be given to the IL-23 inhibitor on the planet, with Skyrizi winning
iData ResearchAbbVie Announces International Skyrizi Approval
Register to receive a free Global Immunology Drugs Market Report Suite report synopsis and brochure The United States Food and Drug Administration (FDA) has recently issued an alert regarding Xeljans (tofacitinib) in treating rheumatoid arthritis patients. The public alert stated that a safety clinical trial found a heightened risk of blood clots in the lungs leading to
iData ResearchTrial Finds Heightened Blood Clot Risk with High Xeljanz Doses, FDA Alerts
Register to receive a free Europe Market Report Suite for Immunology Drugs report synopsis and brochure Sandoz, a biosimilar developer, recently announced the launch of their Hyrimoz product in Spain. The biosimilar references and is approved for all adalimumab (Humira) indications and was authorized for sale in the European Union in July of last year.
iData ResearchSandoz Launches Adalimumab Biosimilar in Spain
Register to receive a free Global Immunology Drugs Market Report Suite report synopsis and brochure The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active ulcerative
iData ResearchJanssen Submits Application To U.S. FDA Seeking Approval Of STELARA® (ustekinumab) For Treatment Of Moderately To Severely Active Ulcerative Colitis
Register to receive a free Global Immunology Drugs Market report synopsis and brochure By Kamran Zamanian and Jacqueline Ding, iData Research Inc. The United States is still an emerging market for biosimilars due to unclear regulatory requirements and unresolved lawsuits pertaining to patent expirations. In 2017, the total market for immunological biosimilars was valued at $240.5
iData ResearchMedicare Coverage Changes Could Significantly Impact Biosimilar Adoption
Register to receive a free Global Immunology Drugs Market Report Suite 2018-2024 report synopsis and brochure Eli Lilly and Company announced Taltz® (ixekizumab) met the primary and all major secondary endpoints in the Phase 3b/4 SPIRIT-H2H study, which evaluated the efficacy and safety of Taltz versus Humira® (adalimumab) in patients with active psoriatic arthritis (PsA) who are biologic disease-modifying
iData ResearchLilly Announces Positive Top-Line Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
Register to receive a free Global Immunology Drugs Market Report Suite 2018-2024 report synopsis and brochure Jecure Therapeutics Inc., a biotechnology company with novel drug discovery programs targeting serious inflammatory diseases, announced a definitive agreement by which it will be acquired by Genentech, a member of the Roche Group. With this acquisition, Genentech will obtain full rights